HT Capital
VC Fund
HT Capital is a VC fund focused on Biotechnology and Health Care. HT Capital, an establishment under Hongtao (HT) Asset Management has been actively investing since 1999. The management team, based between Beijing and Hong Kong covers a full-spectrum of investment activities and strategic portfolio managements in varies sectors including Healthcare, IT and the TMT industry.
- Total investments:
- 16
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries HT Capital invests in
Stages HT Capital invests in
Countries HT Capital invests in
Investment Focus
Industry
- Biotechnology 7 (44%)
- Health Care 3 (19%)
- Manufacturing 3 (19%)
- Pharmaceutical 3 (19%)
- Biopharma 2 (13%)
Stage
- Series B 4 (25%)
- Series A 3 (19%)
- Series C 3 (19%)
- Seed 2 (13%)
- Series D 1 (6%)
Country
- United States 6 (38%)
- China 5 (31%)
- Japan 2 (13%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
TBook
|
TBook is a full-stack, chain-agnostic infrastructure layer designed for the digital workforce. | Seed / Jan 09, 2026 | |
|
TBook
|
TBook is a full-stack, chain-agnostic infrastructure layer designed for the digital workforce. | $5M / Seed / Oct 10, 2025 | |
Uhnder
|
Uhnder is a start-up developing products for sensing, cognition, and communication for the Internet of Things (IoT) market. It is headquartered in California with engineering and operations based in Austin and St. Louis.Uhnder develops a digital automotive radar-on-chip designed to automate systems for safety and better feedback response. Uhnderdisrupts the autonomous vehicle business with what it says is a more accurate and reliable alternative to light detection and ranging, known as lidar, which is one of the most common technologies used to make vehicles more aware of their surroundings.Uhnder's chip helps to avoid collisions, alerts to potential problems, helps with quick localization, as electronic fences for navigation and localization and for communication. | $50M / Series D / Feb 21, 2024 | |
Kula Bio
|
Kula Bio specializes in sustainable, biological solutions for modern agriculture. It energizes nitrogen-fixing microbes to produce organic fertilizer. By rewiring the energy flow from the sun to soil, they are disrupting synthetic fertilizer to eliminate the division between affordable practices and stewardship of our land, sea, and air.Thecompany was founded in 2018 and is headquartered in Somerville, Massachusetts. | $50M / Series A / Jan 03, 2022 | |
TriArm Therapeutics
|
TriArm Therapeutics is a cell therapy company formed by Panacea Venture with R&D operations in Germany, United States and Greater China region. The company focuses on the research and clinical transformation of CD19 CAR-T product using non-viral gene transfer technology, which greatly reduces the cost and time of cell therapy productpreparation, enabling better tumor therapy outcome. | $60M / Venture - Series Unknown / Sep 27, 2021 | |
Alebund Pharmaceuticals
|
Alebund Pharmaceuticals is a biopharmaceutical company dedicated to developing innovative therapies for the treatment of renal diseases and related chronic conditions. | $54.5M / Series B / Sep 13, 2021 | |
JOINN Biologics
|
JOINN Biologics is a California Bay Area-based company that is committed to the advancement of biotech and biopharmaceutics through our premier contract manufacturing and development services for biologics and advanced therapies. A vital part of the JOINN Family's successful 20+ year track record of supporting drug discovery and development,we provide a complete range of CDMO services, from early development to clinical manufacturing, for our clients and partners on a global scale.Core Capabilities • Molecular/developability assessment• cGMP clinical trial materials production• Commercial-scale cGMP manufacturing• Non-GMP protein expression and purification• Cell line development• Upstream process development• Downstream purification development• Analytical and formulation development• Documentation and reporting to support regulatory filingsMissionIt is our mission to provide our global clients and partners with a complete range of premier contract development and manufacturing services for biologics and advanced therapies, from early custom development to clinical manufacturing, to further accelerate the development of high-quality biologics, meeting patients' needs and delivering long-lasting value to the biotech and biopharmaceutical industry. | $150M / Series B / Aug 01, 2021 | |
ImageneBio
|
It is a leading biotech company focused on immunology-related therapeutic areas. | $100M / Series C / Jun 01, 2021 | |
LeJian
|
LeJian is a managed healthcare and insurance service provider. They offer individuals and enterprises all-around customized and intelligent services in health, medical treatment, insurance, welfare, and so on. They provide full-process services from disease prevention to treatment, such as health check-ups, sports health, genetic testing, onlineconsultations, medical guidance, and medical assistance. | Series A / Sep 25, 2020 | |
LandSpace
|
LandSpace is a Chinese company engaged in the development and operation of rockets. Focusing on the small and medium-sized commercial aerospace application market, the company is committed to the development of liquid fuel rocket engines and commercial launch vehicles with independent intellectual property rights. It designs, manufactures, andtests products with highly integrated design capabilities and stand-alone innovation capabilities. The company is a member of the International Astronautical Federation (IAF) and a national high-tech enterprise. It is based in Beijing, China | $175.6M / Series C / Sep 09, 2020 | |
| See all 16 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does HT Capital invest in?
HT Capital invests primarily in Biotechnology, Health Care and Manufacturing startups, most often at Series B and Series A stage. Most of the 16 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did HT Capital last invest?
The most recent investment recorded for HT Capital closed in Jan 2026. Shizune tracks 16 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
